antivenom
prepar
intact
fragment
f
ab
fab
immunoglobulin
g
igg
use
human
medicin
treat
sever
envenom
result
bite
sting
variou
anim
snake
spider
scorpion
marin
anim
contact
poison
plant
obtain
fraction
plasma
collect
immun
hors
less
frequent
sheep
manufactur
process
usual
includ
pepsin
digest
acid
ph
papain
digest
ammonium
sulphat
precipit
capryl
acid
precipit
heat
coagul
andor
chromatographi
product
process
deliber
introduc
viral
inactiv
remov
treatment
antivenom
never
found
transmit
virus
human
nevertheless
recent
exampl
zoonot
diseas
highlight
need
perform
care
assess
viral
safeti
antivenom
paper
review
characterist
equin
virus
antivenom
discuss
potenti
manufactur
step
avoid
risk
viral
contamin
analysi
product
paramet
indic
acid
ph
treatment
capryl
acid
precipit
valid
manufactur
human
igg
product
appear
provid
best
potenti
viral
inactiv
antivenom
mani
manufactur
antivenom
locat
develop
countri
lack
resourc
conduct
formal
viral
valid
studi
hope
review
help
scientif
understand
viral
safeti
factor
antivenom
control
implement
manufactur
step
expect
impact
viral
safeti
overal
reinforc
good
manufactur
practic
essenti
therapeut
product
antivenom
import
biopharmaceut
product
made
plasma
immun
hors
sheep
use
human
medicin
treat
potenti
sever
pathophysiolog
complic
result
bite
sting
variou
anim
snake
scorpion
spider
cnidarian
lepidopteran
fish
well
intox
plant
envenom
seriou
health
problem
worldwid
particularli
dread
rural
area
develop
world
shortag
antivenom
product
lack
suffici
medic
facil
explain
numer
fatal
snake
bite
repres
major
caus
envenom
case
fatal
associ
snake
bite
reach
reduc
less
antivenom
therapi
avail
current
treatment
global
mortal
snake
bite
may
rang
per
year
figur
like
underestim
viperid
snake
bite
envenom
induc
local
effect
swell
pain
necrosi
hemorrhag
blister
often
accompani
secondari
infect
system
viperid
envenom
character
complex
pathophysiolog
profil
includ
coagulopathi
hemorrhag
hypovolaemia
shock
acut
renal
failur
progress
paralysi
may
caus
elapid
snake
venom
neurotoxin
viperid
venom
display
neurotox
effect
elapid
venom
also
induc
local
necrosi
rhabdomyolysi
snake
bite
survivor
may
major
chronic
physic
neurolog
disabl
scorpion
sting
second
major
caus
human
fatal
envenom
probabl
amount
sever
hundr
per
year
scorpion
venom
contain
toxin
target
sodium
potassium
calcium
chlorid
channel
caus
direct
effect
releas
neutrotransmitt
acetylcholin
catecholamin
induc
intens
local
pain
potenti
fatal
neurotox
hemodynam
disturb
role
antivenom
treatment
scorpion
sting
arachnid
remain
controversi
sever
report
support
manufactur
use
particularli
sever
case
fatal
also
occur
envenom
jellyfish
venom
fish
longterm
anecdot
experi
support
benefici
effect
stonefish
antivenom
may
need
given
earli
fight
rapid
onset
cardiotox
sting
cnidarian
lepidoptera
centiped
coneshel
bite
spider
tick
one
genu
octopu
probabl
account
death
per
year
final
envenom
massiv
attack
africanis
bee
caus
death
year
america
antivenom
often
made
fraction
plasma
hors
less
frequent
sheep
immun
crude
venom
pool
hyperimmun
plasma
process
purifi
hors
immunoglobulin
g
igg
fraction
may
subject
enzymat
treatment
obtain
f
ab
fab
antibodi
fragment
capryl
ammonium
sulphat
precipit
improv
puriti
extent
manufactur
step
featur
similar
use
prepar
human
plasmaderiv
igg
although
known
transmiss
infecti
agent
antivenom
albeit
circumst
rigor
clinic
patient
followup
difficult
theoret
concern
possibl
transmiss
horsesheep
infecti
agent
human
exist
recent
natur
transmiss
zoonot
diseas
highlight
possibl
exchang
human
natur
reservoir
biolog
agent
found
anim
inher
risk
emerg
diseas
exampl
infect
origin
anim
avian
pathogen
includ
human
immunodefici
viru
ebola
hantaan
lassa
nipah
virus
paramyxovirus
equin
morbilli
viru
west
nile
viru
probabl
sever
acut
respiratori
syndrom
sar
coronaviru
parenter
transmiss
anim
virus
human
also
possibl
infecti
viru
rhesu
monkey
contamin
earli
polio
vaccin
administ
larg
number
peopl
whether
way
viru
introduc
human
popul
unclear
controversi
issu
risk
contamin
antivenom
equin
viru
therefor
theoret
concern
debat
recent
world
health
organ
workshop
recent
committe
proprietari
medicin
product
cpmp
european
medicin
evalu
agenc
publish
note
guidanc
manufactur
qualiti
control
anim
immunoglobulin
immunsera
howev
manufactur
antivenom
locat
develop
world
may
directli
expos
stateoftheart
process
valid
concept
financi
logist
capabl
perform
extens
viral
valid
studi
assess
viral
reduct
potenti
process
use
therefor
found
help
examin
viral
safeti
antivenom
first
review
characterist
equin
virus
evalu
theoret
abil
manufactur
method
antivenom
inactiv
remov
virus
comparison
well
valid
technolog
use
manufactur
human
plasmaderiv
igg
prepar
final
want
emphas
appli
good
manufactur
practic
product
antivenom
control
anim
product
step
ensur
traceabl
whole
chain
manufactur
repres
current
best
invest
qualiti
safeti
product
hors
harbour
envelop
nonenvelop
virus
main
structur
characterist
virus
present
tabl
epidemiolog
clinic
data
test
method
describ
briefli
eav
nm
singlestrand
ss
rna
viru
arterivirida
famili
eav
caus
equin
viral
arter
endotheliotrop
viral
diseas
transmiss
occur
via
respiratori
reproduct
rout
varieti
clinic
sign
strain
vari
virul
sever
infect
lead
abort
pregnant
mare
neonat
foal
death
onetub
realtim
taqman
rtpcr
assay
develop
detect
eav
test
valid
use
semin
plasma
nasal
secret
dna
vaccin
shown
induc
longterm
immun
bdv
nm
ssrna
viru
belong
new
bornavirida
famili
order
mononegaviral
borna
diseas
known
diseas
head
sporad
occur
progress
viral
polioencephalomyel
primarili
affect
hors
sheep
week
sever
month
incub
bdv
caus
locomotor
sensori
dysfunct
follow
paralysi
death
bdv
exist
worldwid
hors
sheep
cattl
cat
dog
ostrich
affect
larg
number
warmblood
anim
speci
includ
human
infect
fatal
major
carrier
asymptomat
crossspeci
transmiss
commens
viru
proven
zoonot
aspect
bdv
consid
bdvspecif
antibodi
viral
rna
found
human
variou
psychiatr
disord
diagnosi
made
serolog
also
antigen
marker
peripher
white
blood
cell
combin
nucleic
acid
amplif
close
relat
nm
ssrna
alphavirus
arboviru
type
togavirida
famili
transmit
arthropod
usual
mosquito
symptom
eeev
infect
import
multisystem
zoonot
diseas
includ
anorexia
colic
chang
sensorium
hyperexcit
termin
sever
depress
organ
coagul
necrosi
cn
lesion
observ
weev
neuroinvas
eeev
enceph
caus
sever
caus
eeev
test
detect
eee
wee
viral
rna
recent
develop
veev
present
human
hors
evid
transmiss
hors
human
normal
rout
contamin
found
veev
identifi
pharyng
secret
stabl
aerosol
shown
stabl
dri
blood
exud
vaccin
develop
three
virus
one
possibl
case
viral
transmiss
hors
suspect
follow
vaccin
ecv
nm
ssrna
viru
coronavirida
famili
isol
fece
diarrhoeic
foal
close
antigen
andor
genet
relationship
mammalian
group
coronavirus
efv
also
known
spumaviru
nm
ssrna
viru
retrovirida
famili
belong
nonpathogen
complex
unconvent
retrovirus
isol
nonhuman
primat
cattl
cat
recent
blood
hors
ehv
larg
nm
doublestrand
ds
dna
gamma
herp
virus
caus
much
damag
hors
industri
ubiquit
equin
popul
respons
lifelong
latent
infect
host
even
natur
vaccineinduc
immun
strain
associ
respiratori
diseas
abort
paresisparalysi
wherea
strain
induc
respiratori
diseas
less
clear
pathogen
distribut
within
equin
popul
may
aetiolog
role
ocular
diseas
preval
adult
hors
found
sweden
unit
kingdom
preval
dna
adult
hors
hungari
unit
kingdom
respect
eiav
nm
ssrna
lentiviru
retrovirida
famili
hiv
infect
hors
asymptomat
lifelong
latent
infect
leucocyt
stress
eg
pregnanc
corticosteroid
surgic
oper
diseas
new
viru
variant
aris
viraemia
increas
red
blood
cell
becom
coat
viru
particl
lyse
complement
caus
jaundic
oedema
hemorrhag
diarrhoea
petechi
hemorrhag
eiav
transmit
hors
hors
blood
recent
reversetranscriptas
polymeras
chain
reaction
assay
rtpcr
describ
quantifi
eiav
rna
equin
plasma
eiv
nm
ssrna
viru
orthomyxovirida
equin
influenza
one
econom
import
contagi
respiratori
diseas
hors
hev
nm
ssrna
viru
viru
probabl
transmit
bat
hors
caus
natur
diseas
human
hors
refer
viru
propos
new
genu
within
paramyxovirida
famili
also
includ
anoth
newli
identifi
zoonot
bat
viru
nipah
salem
viru
hev
recogn
australia
new
zoonot
diseas
hors
sinc
lethal
zoonot
viral
agent
endem
certain
speci
fruit
bat
flyingfox
eastern
australia
seroposit
six
speci
flyingfox
papua
new
guinea
test
posit
antibodi
hev
hev
appear
transmit
readili
hors
natur
experiment
condit
hors
human
hors
infect
oronas
rout
excret
hev
urin
saliva
viru
appear
spread
close
contact
bodi
fluid
froth
infect
lung
via
nasal
discharg
saliva
andor
urin
import
clinic
patholog
manifest
hev
infect
hors
human
sever
interstiti
pneumonia
caus
viral
infect
small
blood
vessel
epizoot
epidemiolog
episod
meningoenceph
sever
acut
respiratori
syndrom
report
australia
malaysia
singapor
may
also
caus
nervou
diseas
three
incid
hev
diseas
hors
record
australiadtwo
caus
death
two
human
hors
one
involv
death
singl
hors
infect
hors
develop
sever
often
fatal
respiratori
diseas
character
dyspnoea
vascular
endotheli
damag
pulmonari
oedema
nervou
sign
may
also
occur
number
diagnost
method
develop
base
examin
blood
lung
kidney
spleen
nervou
sign
present
also
brain
pcr
assay
develop
rapid
sensit
rtpcr
assay
use
fluorogen
taqman
probe
develop
improv
diagnosi
hev
infect
close
relat
arthropodborn
nm
ssrna
flavivirus
flavivirida
famili
may
affect
central
nervou
system
hors
evid
infect
niv
found
brain
one
hors
inflamm
mening
blood
vessel
occur
niv
emerg
malaysia
spread
rapidli
pig
popul
caus
death
peopl
salv
recent
identifi
hors
known
isol
obtain
hors
involv
diseas
outbreak
undetermin
natur
vsv
nm
ssrna
viru
rhabdovirida
famili
may
caus
stomat
hors
may
repres
emerg
equin
infecti
diseas
immunoglobulin
igm
captur
enzymelink
immunosorb
assay
mcelisa
develop
detect
primari
infect
vsv
equin
swine
sera
wnv
nm
ssrna
arboviru
flavivirida
famili
first
identifi
west
nile
district
uganda
wnv
found
broad
geograph
rang
wide
divers
vertebr
host
vector
speci
diseas
found
african
european
eurasian
countri
recent
increas
outbreak
ill
due
wnv
anim
well
human
numer
case
current
report
canada
usa
infect
human
may
asymptomat
transfus
donat
blood
individu
result
infect
death
recipi
led
introduct
strict
regulatori
measur
canada
usa
includ
test
pcr
assay
blood
donat
wnv
primarili
circul
bird
mosquito
mammalian
infect
incident
mammal
bite
mosquito
becom
infect
feed
blood
infect
bird
happen
peopl
hors
mammal
may
get
wnv
infect
hors
howev
unlik
serv
import
amplifi
host
wnv
natur
mani
wnvinfect
hors
probabl
never
show
symptom
studi
report
mortal
rate
close
earli
symptom
often
indistinguish
equin
encephalitid
includ
rabi
equin
equin
protozo
myeloenceph
eastern
western
venezuelan
equin
encephalomyel
vaccin
hors
develop
one
hors
receiv
two
dose
die
diseas
erav
erbv
picornavirus
reclassifi
member
aphtoviru
genu
resembl
footandmouth
diseas
viru
nm
ssrna
virus
high
neutral
antibodi
titer
develop
appear
correl
strong
reactiv
western
blot
new
serotyp
genu
erboviru
tent
name
identifi
recent
found
hors
australia
eev
nm
dsrna
viru
reovirida
famili
sever
serotyp
identifi
southern
africa
serotypespecif
virusneutr
antibodi
serum
sampl
hors
suggest
widespread
occurr
infect
seem
low
level
crossprotect
hors
natur
reinfect
erv
nm
doublestrand
rna
reovirida
rotavirus
import
pathogen
associ
diarrhoeal
diseas
almost
speci
mammal
pcr
test
detect
limit
approxim
per
gram
faec
possibl
increas
sensibl
one
order
magnitud
use
nest
pcr
develop
repres
possibl
diagnost
tool
antivenom
produc
plasma
serum
collect
immun
hors
sheep
plasma
obtain
centrifug
whole
blood
apheresi
plasma
sever
anim
typic
pool
l
batch
subject
fraction
process
isol
igg
fraction
follow
initi
use
crude
equin
immun
serum
still
report
manufactur
one
produc
variou
method
igg
purif
refin
introduc
tabl
manufactur
use
protocol
deriv
basic
method
describ
pope
modifi
harm
base
pepsin
digest
low
ph
obtain
f
ab
fragment
follow
ammonium
sulphat
precipit
antibodi
fragment
basic
approach
combin
number
addit
step
aim
obtain
purer
prepar
heat
coagul
ionexchang
chromatographi
ph
pepsin
digest
perform
variou
laboratori
rang
temperatur
c
pepsin
digest
usual
perform
undilut
serum
plasma
protein
concentr
gl
incub
time
rang
min
h
vari
pepsin
concentr
thermocoagul
use
mani
laboratori
consist
heat
c
h
although
method
involv
pepsin
digest
includ
heat
coagul
fraction
protocol
includ
addit
tabl
step
use
manufactur
antivenom
screen
product
anim
adventiti
agent
plasma
collect
whole
blood
apheresi
bag
bottl
plasma
thaw
room
temperatur
plasma
pool
iggfrag
purif
process
f
ab
b
pepsin
digest
acid
ph
ammonium
sulphat
precipit
b
pepsin
digest
acid
ph
capryl
acid
precipit
fab
ammonium
sulphat
precipit
papain
digest
ph
whole
igg
b
capryl
acid
precipit
b
ammonium
sulphat
precipit
iggfrag
concentr
nh
na
precipit
ultrafiltr
polish
ion
exchang
remov
fc
purifi
igg
fragment
ultrafiltr
steril
filtrat
asept
fill
storag
liquid
state
lyophilis
acidif
step
remov
nonigg
globulin
euglobulin
unstabl
acid
ph
one
produc
includ
bulk
pasteuris
step
antivenom
product
protocol
manufactur
produc
whole
igg
antivenom
use
either
ammonium
sulphat
precipit
igg
capryl
acid
precipit
nonigg
protein
follow
dialysi
ultrafiltr
recent
simpl
onestep
methodolog
base
capryl
acid
precipit
describ
condit
use
capryl
acid
fraction
equin
plasma
follow
plasma
ph
adjust
capryl
acid
ad
directli
plasma
attain
final
concentr
vv
mixtur
stir
capryl
acid
addit
one
addit
hour
precipit
separ
filtrat
capryl
acid
remov
either
dialysi
ultrafiltr
product
formul
steril
filtrat
antivenom
made
fab
antibodi
fragment
obtain
papain
digest
sheep
igg
neutral
ph
sodium
sulphat
precipit
igg
affinitychromatographi
ionexchang
chromatographi
step
describ
product
fab
antivenom
treatment
bpropiolacton
evalu
reduc
complement
activ
hors
plasmaderiv
product
howev
appear
use
routin
laboratori
produc
antivenom
addit
differ
fraction
protocol
antivenom
made
whole
igg
f
ab
fab
molecul
greatli
differ
pharmacokinet
profil
antivenom
come
liquid
present
lyophil
former
need
store
c
sinc
higher
temperatur
reduc
shelflif
induc
protein
denatur
aggreg
format
contrast
lyophil
antivenom
store
room
temperatur
prolong
shelflif
antivenom
contain
preserv
prevent
bacteri
contamin
consider
experi
gain
recent
year
viral
safeti
human
igg
prepar
human
plasmaderiv
product
histor
perspect
product
help
assess
viral
safeti
antivenom
safeti
human
plasma
product
result
combin
overlap
strategi
includ
select
donor
b
viral
test
procedur
singl
donat
eg
serolog
test
plasma
pool
eg
nucleic
acid
test
exclud
donat
contamin
virus
c
process
purif
step
inactiv
remov
virus
implement
good
manufactur
practic
whenev
feasibl
similar
approach
use
manufactur
anim
plasmaderiv
product
monitor
health
anim
use
antivenom
product
import
coloni
anim
kept
free
contamin
good
husbandri
vaccin
appropri
surveil
sourc
anim
includ
screen
pathogen
health
monitor
includ
routin
blood
chemistri
haematolog
test
postmortem
examin
ideal
anim
kept
strictli
contain
condit
readili
applic
hors
howev
instanc
anim
could
kept
free
particular
arthropodborn
viru
maintain
area
free
particular
arthropod
vector
particular
pathogen
identifi
establish
whether
present
plasma
virolog
screen
method
may
perform
avail
epidemiolog
relev
particular
geograph
region
limit
risk
viru
presenc
anim
herd
andor
plasma
pool
extent
guidelin
feder
european
laboratori
anim
scienc
associ
felasa
although
refer
hors
may
serv
refer
nevertheless
measur
avail
mani
develop
countri
readili
applic
hors
use
antivenom
product
pathogen
escap
surveil
program
illustr
need
manufactur
techniqu
ensur
suffici
margin
safeti
regard
potenti
infecti
agent
present
manufactur
plasma
pool
also
strongli
emphas
crucial
import
ensur
appropri
traceabl
system
hors
donor
human
recipi
antivenom
potenti
infecti
event
risk
may
identifi
proper
time
manner
relev
countermeasur
taken
promptli
confid
safeti
antivenom
must
come
evid
manufactur
process
use
reproduc
remov
inactiv
high
potenti
level
virus
comparison
human
plasma
fraction
suggest
step
antivenom
includ
treatment
may
inactiv
virus
human
plasma
fraction
complex
integr
manufactur
process
product
like
albumin
coagul
factor
igg
obtain
purif
process
combin
cryoprecipit
ethanol
fraction
chromatographi
ultrafiltr
addit
variou
type
dedic
viral
reduct
treatment
introduc
often
purpos
chemic
treatment
solventdeterg
capryl
acid
precipit
lowph
incub
heat
treatment
liquid
dri
state
nanofiltr
among
capryl
acid
low
ph
treatment
commonli
use
also
purif
antivenom
igg
shown
contribut
viral
safeti
human
plasma
igg
product
describ
year
ago
unsatur
fatti
acid
shown
experiment
inactiv
log
lipidenvelop
virus
vsv
sindbi
viru
hiv
human
plasma
protein
fraction
howev
specif
attent
given
capryl
acid
also
call
octano
acid
use
precipit
agent
human
igg
suggest
nonion
form
capryl
acid
disrupt
integr
lipid
bilay
membran
associ
protein
envelop
virus
util
dissoci
reaction
vari
concentr
ioniz
form
capryl
specif
amount
nonion
form
capryl
maintain
wide
ph
rang
treatment
plasma
protein
solut
capryl
acid
ph
also
readili
inactiv
lipidenvelop
virus
like
herp
simplex
viru
type
vesicular
stomat
viru
vaccinia
viru
sindbi
viru
detail
valid
studi
two
capryl
acid
treatment
human
ig
publish
recent
robust
treatment
appli
three
intraven
immunoglobulin
prepar
igg
igmenrich
igm
prepar
investig
use
hiv
bvdv
sindbi
viru
pseudorabi
model
virus
routin
treatment
condit
two
igg
igm
prepar
indic
tabl
kinet
inactiv
determin
period
h
treatment
complet
inactiv
correspond
log
achiev
within
first
minut
within
certain
rang
viral
inactiv
igg
product
affect
ph
temperatur
c
protein
content
gl
ph
specif
ph
bvdv
inactiv
found
content
capryl
acid
gkg
less
inactiv
hiv
significantli
reduc
condit
appli
manufactur
capryl
acid
lead
robust
inactiv
lipidenvelop
virus
ph
particularli
critic
paramet
less
condit
also
found
inactiv
eav
equin
viru
use
model
person
commun
anoth
studi
report
viral
inactiv
achiev
capryl
acid
precipit
nonigg
protein
human
igg
product
ph
c
presenc
mm
capryl
r
r
log
hiv
prv
respect
inactiv
h
treatment
log
bvdv
inactiv
mm
capryl
r
log
bvdv
inactiv
within
time
period
ph
c
mm
capryl
ph
c
mm
capryl
complet
inactiv
bvdv
hiv
prv
achiev
less
min
author
also
show
mm
capryl
ph
c
supernat
intermedi
albumin
product
inactiv
r
log
bvdv
almost
instantan
virucid
effect
capryl
acid
also
confirm
human
albumin
solut
use
stabil
pasteuris
elev
temperatur
low
ph
found
critic
paramet
ensur
signific
reduct
viru
infect
rate
extent
inactiv
sensit
variat
capryl
protein
ratio
chang
ph
condit
retain
wv
protein
mm
capryl
ph
c
log
inactiv
lipidenvelop
virus
test
includ
bvdv
achiev
kept
mind
treatment
whole
plasma
crude
fraction
case
equin
antivenom
product
may
lead
lower
rate
kinet
viral
inactiv
due
high
endogen
lipid
content
found
studi
evalu
virucid
effect
sodium
oleat
final
one
keep
mind
capryl
acid
treatment
inactiv
nonenvelop
virus
sever
human
igg
prepar
subject
acid
ph
incub
histor
introduc
reduc
immedi
advers
reaction
subsequ
intraven
inject
late
acid
ph
treatment
also
shown
contribut
greatli
tabl
comparison
condit
capryl
acid
treatment
use
human
igg
prepar
treatment
human
igg
gener
consist
incub
ph
without
trace
pepsin
temperatur
c
use
protein
content
close
gl
h
treatment
intend
elimin
aggreg
pepsin
present
maintain
low
concentr
avoid
cleavag
igg
molecul
sever
model
envelop
virus
shown
inactiv
condit
log
inactiv
hiv
envelop
virus
use
surrog
model
semliki
forest
viru
sfv
hsv
vsv
cmv
achiev
contrast
polioviru
nonenvelop
viru
seem
resist
presenc
trace
concentr
pepsin
ad
reduc
anticomplementari
activ
procedur
shown
contribut
littl
viru
kill
process
viru
inactiv
acid
ph
pepsin
influenc
sever
paramet
hiv
bvdv
sfv
prv
complet
inactiv
within
h
c
inactiv
rate
extent
less
lower
temperatur
increas
sucros
content
reduc
rate
inactiv
prv
sfv
increas
nacl
content
mm
reduc
rate
inactiv
sfv
prv
unchang
increas
igg
concentr
speed
inactiv
prv
decreas
sfv
therefor
temperatur
major
paramet
virucid
efficaci
phpepsin
treatment
impact
solut
composit
virusdepend
fraction
protocol
use
antivenom
product
includ
low
ph
treatment
induc
precipit
euglobulin
plasma
globulin
unstabl
condit
step
shown
remov
log
eiav
sindbi
viru
polioviru
porcin
parvoviru
viru
reduct
may
occur
coprecipit
discard
euglobulin
rather
inactiv
process
pasteuris
treatment
liquid
protein
fraction
h
c
use
product
least
one
type
equinederiv
antivenom
experi
human
plasma
product
show
liquid
heat
treatment
may
inactiv
envelop
nonenvelop
virus
pasteuris
albumin
solut
carri
final
contain
presenc
low
concentr
sodium
capryl
alon
nacetyl
tryptophan
inactiv
sindbi
emc
model
virus
ad
albumin
solut
achiev
within
min
treatment
howev
inactiv
nonenvelop
virus
less
process
appear
virusspecif
variou
coagul
factor
proteas
inhibitor
intraven
igg
pasteuris
purif
process
often
pasteuris
perform
presenc
stabil
like
amino
acid
sugar
citrat
protect
protein
function
limit
molecular
alter
protein
aggreg
protein
stabil
also
known
stabil
virus
howev
highlight
need
valid
exact
condit
treatment
use
pasteuris
inactiv
virus
differ
type
envelop
nonenvelop
includ
hiv
hbv
hcv
hav
publish
data
inactiv
resist
model
nonenvelop
virus
like
porcin
parvoviru
sv
reoviru
type
plasma
product
instanc
inactiv
virus
limit
less
log
h
heat
period
heat
treatment
whole
human
plasma
c
h
presenc
specif
combin
stabil
inactiv
log
hiv
log
envelop
nonenvelop
model
virus
final
demonstr
heat
treatment
like
pasteuris
vapour
heat
treatment
well
solventdeterg
nanofiltr
nm
membran
inactiv
remov
log
wnv
chromatographi
primarili
use
human
plasma
fraction
downstream
polish
step
ionexchang
chromatographi
describ
antivenom
product
viral
partit
shown
occur
affin
ionexchang
chromatographi
mechan
remov
easi
predict
control
make
difficult
consid
robust
viral
remov
step
storag
ph
presenc
stabil
maltos
minimum
day
c
yield
aggregatefre
vitro
function
activ
human
igg
prepar
incub
ph
day
c
caus
decreas
bvdv
infect
complet
inactiv
chimpanze
infecti
dose
per
millilitr
hcv
except
recent
report
fab
ovin
antivenom
formul
ph
knowledg
formul
low
ph
commonli
use
antivenom
may
consid
viral
safeti
step
affect
biolog
activ
gener
safeti
clinic
efficaci
product
viral
valid
studi
smallscal
experi
design
provid
estim
overal
viral
reduct
level
achiev
across
manufactur
process
identifi
step
paramet
critic
viral
inactiv
remov
perform
studi
describ
guidelin
prepar
cpmp
product
intermedi
voluntarili
spike
known
amount
known
virus
use
laboratoryscal
mimick
product
process
viru
reduct
factor
calcul
compar
infect
level
individu
process
step
evalu
appropri
cumul
viral
reduct
factor
calcul
provid
inform
viral
safeti
margin
process
rang
model
virus
effect
robust
individu
step
typic
achiev
log
reduct
infect
larg
rang
product
paramet
viral
valid
studi
usual
conduct
model
virus
differ
structur
featur
presenc
envelop
rna
dna
genet
materi
size
degre
resist
relev
virus
known
potenti
contamin
start
plasma
use
possibl
list
exist
laboratori
adapt
model
virus
could
use
valid
studi
antivenom
manufactur
process
shown
tabl
vsv
wnv
may
contamin
hors
appear
special
relev
process
valid
equin
product
dedic
viral
inactiv
remov
product
step
implement
way
ensur
reproduc
viral
reduct
absenc
risk
downstream
contamin
exampl
approach
use
manufactur
human
plasma
product
provid
recent
guidelin
cpmp
note
guidanc
provid
recommend
product
immunsera
use
refer
manufactur
antivenom
viral
reduct
equip
adapt
specif
instanc
equip
bulk
process
viru
inactiv
acid
ph
incub
capryl
acid
treatment
ideal
fulli
enclos
addit
vessel
temperatur
control
design
avoid
dead
point
import
paramet
temperatur
ph
could
ensur
similarli
liquid
heat
treatment
heat
shock
conduct
jacket
tank
solut
stir
throughout
heat
cycl
ensur
homogen
point
tank
within
specifi
temperatur
rang
qualif
phase
equip
requir
servic
shown
conform
predefin
technic
specif
requir
function
within
specifi
limit
possibl
recommend
creat
dedic
viral
safeti
area
product
step
arrang
clear
logic
way
recontamin
viral
reduc
intermedi
avoid
oper
procedur
also
written
reduc
likelihood
crosscontamin
bulk
ph
capryl
acid
viru
inactiv
could
carri
two
stage
first
stage
locat
normal
product
room
follow
second
incub
anoth
tank
locat
segreg
contain
area
durat
first
stage
major
viru
inactiv
found
viral
valid
studi
occur
complet
first
stage
product
asept
transfer
eg
steril
coupl
second
vessel
locat
safeti
zone
complet
second
stage
viral
inactiv
productcontactingequip
use
safeti
area
dedic
decontamin
inactiv
remain
viru
qualiti
assur
system
ensur
execut
viru
reduct
method
conform
valid
condit
viral
inactiv
remov
procedur
describ
approv
standard
oper
procedur
sop
contain
critic
process
limit
viral
inactiv
remov
method
appli
antivenom
date
document
exampl
viral
transmiss
human
use
antivenom
whichev
type
product
whole
igg
f
ab
fab
manufactur
consid
difficulti
contain
larg
anim
like
hors
exhaust
viral
test
start
plasma
viral
safeti
antivenom
appear
therefor
larg
depend
upon
capac
manufactur
process
reduc
infecti
agent
use
good
manufactur
practic
particular
ensur
product
traceabl
contrast
human
plasma
product
antivenom
current
subject
purpos
introduc
viral
reduct
step
like
solventdeterg
pasteuris
nanofiltr
howev
comparison
valid
manufactur
process
use
human
igg
clearli
indic
least
two
wide
use
antivenom
product
step
capryl
acid
treatment
lowph
incub
like
contribut
robust
manner
viral
safeti
least
envelop
virus
concentr
capryl
acid
use
antivenom
higher
use
human
igg
tabl
ph
treatment
within
effect
rang
less
ph
requir
optim
inactiv
envelop
virus
treatment
perform
equin
plasma
crude
fraction
viral
kill
could
reduc
presenc
lipid
acid
incub
antivenom
perform
ph
less
use
human
igg
similarli
warm
temperatur
c
tabl
provid
fast
rate
inactiv
lipidenvelop
virus
possibl
also
nonenvelop
virus
howev
incub
time
h
process
significantli
less
human
igg
typic
h
probabl
reduc
extent
viral
kill
achiev
preliminari
viral
kill
data
obtain
antivenom
confirm
condit
use
peptic
cleavag
low
ph
f
ab
achiev
robust
inactiv
wnv
recommend
repres
viral
valid
studi
use
rang
wellestablish
viru
model
perform
know
rate
extent
viral
kill
actual
achiev
product
step
virus
use
valid
discuss
special
virologist
analog
studi
done
human
plasma
deriv
might
includ
three
lipidenvelop
virus
bvdv
vsv
psr
wnv
one
nonenvelop
viru
emc
polioviru
reoviru
inactiv
data
could
compar
viral
kill
achiev
use
similar
process
step
human
igg
product
therefor
provid
refer
robust
allow
manufactur
nation
regulatori
author
assess
scientif
margin
safeti
antivenom
product
manufactur
step
heat
coagul
could
valid
well
formul
product
low
ph
done
human
igg
prepar
anoth
potenti
approach
consid
improv
viral
safeti
evalu
product
stabil
efficaci
condit
would
prerequisit
view
expect
benefici
impact
viral
safeti
appropri
process
implement
capryl
acid
treatment
lowph
incub
ensur
well
measur
taken
avoid
risk
downstream
contamin
wide
respect
good
manufactur
practic
traceabl
concept
conclus
also
valid
anim
plasmaderiv
igg
product
use
human
medicin
antilymphocytetcel
antitoxin
antibacteri
viral
agent
sera
